Answers are grounded in this paper and cite their sources.
Adjuvant phase III clinical trials in early-stage breast cancer are scientifically important, but sometimes they can be troublesome due to the amount of patients required as well as the long follow-up in order to get the expected number of events. While providing the highest level of evidence in oncology, conducting these trials may take several years or even decades and results may only be available once the question asked is no longer relevant. Furthermore, in recent adjuvant studies, lower than expected recurrence rates resulted in lower statistical power to demonstrate benefit with experimental therapies, thereby requiring alterations to the study design or joint analyses with parallel studies.
No takes yet. Share an insight, caveat, or question.
Bartsch et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: